BOSTON (

TheStreet

) --Welcome to October's Biotech Stock Mailbag Live Chat. The floor is yours.

I'm here for the next 90 minutes to answer your biotech investing questions and hopefully spark some interactive debate on the hot biotech topics of the day. This chat only works if you participate, so please keep the questions and comments flowing in the box below.

Biotech earnings season kicks off in earnest next week, with reports due from

Celgene

(CELG) - Get Report

,

Biogen Idec

(BIIB) - Get Report

,

Amgen

(AMGN) - Get Report

and

Gilead Sciences

(GILD) - Get Report

.

Investors will be paying close attention to

Vertex Pharmaceuticals

(VRTX) - Get Report

when it reports Incivek sales on Oct. 27.

Human Genome Sciences

( HGSI) will be reporting third-quarter Benlysta sales amidst investor concerns about the lupus drug's slow launch. And what about those rumors of a

GlaxoSmithkline

(GSK) - Get Report

takeout?

Optimer Pharmaceuticals

(OPTR)

appears to be bucking the "slow launch" trend with its antibiotic Dificid.

Let's discuss FDA drug approvals:

Onyx Pharmaceuticals

(ONXX)

,

Neoprobe

(NEOP)

,

Incyte

(INCY) - Get Report

,

Alexza Pharmaceuticals

(ALXA)

and

MAP Pharma

( MAPP), among others.

I've raised a ruckus with

Keryx Pharma

(KERX) - Get Report

predicting the failure of the colon cancer drug perifosine, but I'm more than happy to continue the debate today.

Let's talk about these stocks today, or any other biotech investing subjects that pique your interest. Please join me live.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein

.

>To follow the writer on Twitter, go to

http://twitter.com/adamfeuerstein

.

>To submit a news tip, send an email to:

tips@thestreet.com

.

Follow

TheStreet

on

Twitter

and become a fan on

Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.